Risk factors for lower extremity lymphedema after cervical cancer treatment: a systematic review and meta-analysis

The main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment.BackgroundThe main risk factors for the development of lower extremit...

Full description

Saved in:
Bibliographic Details
Published inTranslational cancer research Vol. 11; no. 6; pp. 1713 - 1721
Main Authors Hu, Hongyuan, Fu, Mingru, Huang, Xiujin, Huang, Ju, Gao, Jinniao
Format Journal Article
LanguageEnglish
Published AME Publishing Company 01.06.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment.BackgroundThe main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment.We searched the English database PubMed, Embase, Medline, Central and the Chinese database CNKI to obtain relevant studies. Inclusion criteria: (I) the subjects were cervical cancer patients receiving treatment; (II) cohort studies or case-control studies; (III) exposure factors were not limited; (IV) the outcome was lower extremity lymphedema after treatment; (V) the odds ratio (OR) value and 95% confidence interval of exposure factors can be obtained. The chi-square test was used to test for heterogeneity. The Egger test was used to test for publication bias. OR (95% CI) was calculated using inverse variance.MethodsWe searched the English database PubMed, Embase, Medline, Central and the Chinese database CNKI to obtain relevant studies. Inclusion criteria: (I) the subjects were cervical cancer patients receiving treatment; (II) cohort studies or case-control studies; (III) exposure factors were not limited; (IV) the outcome was lower extremity lymphedema after treatment; (V) the odds ratio (OR) value and 95% confidence interval of exposure factors can be obtained. The chi-square test was used to test for heterogeneity. The Egger test was used to test for publication bias. OR (95% CI) was calculated using inverse variance.A total of 12 retrospective studies with a total of 3,401 patients were included in this literature review. The incidence of lower extremity lymphedema after cervical cancer treatment was between 12.6% and 43.1%. Meta-analysis results demonstrated that the main risk factors were: body mass index (BMI) (OR =1.37, 95% CI: 1.10-1.71, P=0.005), age (OR =1.68, 95% CI: 1.07-2.64, P=0.02), International Federation of Gynecology and Obstetrics (FIGO) stage (OR =1.50, 95% CI: 1.24-1.82, P<0.001), radiotherapy (OR =2.87, 95% CI: 1.71-4.82, P<0.001), lymph node (LN) dissection (OR =3.24, 95% CI: 1.44-7.31, P=0.005), and the number of LNs dissected (OR =2.34, 95% CI: 1.80-3.05, P<0.001). Egger's test showed that there was no publication bias among the literatures (P>0.05).ResultsA total of 12 retrospective studies with a total of 3,401 patients were included in this literature review. The incidence of lower extremity lymphedema after cervical cancer treatment was between 12.6% and 43.1%. Meta-analysis results demonstrated that the main risk factors were: body mass index (BMI) (OR =1.37, 95% CI: 1.10-1.71, P=0.005), age (OR =1.68, 95% CI: 1.07-2.64, P=0.02), International Federation of Gynecology and Obstetrics (FIGO) stage (OR =1.50, 95% CI: 1.24-1.82, P<0.001), radiotherapy (OR =2.87, 95% CI: 1.71-4.82, P<0.001), lymph node (LN) dissection (OR =3.24, 95% CI: 1.44-7.31, P=0.005), and the number of LNs dissected (OR =2.34, 95% CI: 1.80-3.05, P<0.001). Egger's test showed that there was no publication bias among the literatures (P>0.05).BMI, age, FIGO stage, radiotherapy, LN dissection and the number of LNs removed are the main risk factors for lower extremity lymphedema after cervical cancer treatment. When treating patients with cervical cancer, effective interventions should be sought to reduce the risk of lower extremity edema.ConclusionsBMI, age, FIGO stage, radiotherapy, LN dissection and the number of LNs removed are the main risk factors for lower extremity lymphedema after cervical cancer treatment. When treating patients with cervical cancer, effective interventions should be sought to reduce the risk of lower extremity edema.
AbstractList The main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment.BackgroundThe main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment.We searched the English database PubMed, Embase, Medline, Central and the Chinese database CNKI to obtain relevant studies. Inclusion criteria: (I) the subjects were cervical cancer patients receiving treatment; (II) cohort studies or case-control studies; (III) exposure factors were not limited; (IV) the outcome was lower extremity lymphedema after treatment; (V) the odds ratio (OR) value and 95% confidence interval of exposure factors can be obtained. The chi-square test was used to test for heterogeneity. The Egger test was used to test for publication bias. OR (95% CI) was calculated using inverse variance.MethodsWe searched the English database PubMed, Embase, Medline, Central and the Chinese database CNKI to obtain relevant studies. Inclusion criteria: (I) the subjects were cervical cancer patients receiving treatment; (II) cohort studies or case-control studies; (III) exposure factors were not limited; (IV) the outcome was lower extremity lymphedema after treatment; (V) the odds ratio (OR) value and 95% confidence interval of exposure factors can be obtained. The chi-square test was used to test for heterogeneity. The Egger test was used to test for publication bias. OR (95% CI) was calculated using inverse variance.A total of 12 retrospective studies with a total of 3,401 patients were included in this literature review. The incidence of lower extremity lymphedema after cervical cancer treatment was between 12.6% and 43.1%. Meta-analysis results demonstrated that the main risk factors were: body mass index (BMI) (OR =1.37, 95% CI: 1.10-1.71, P=0.005), age (OR =1.68, 95% CI: 1.07-2.64, P=0.02), International Federation of Gynecology and Obstetrics (FIGO) stage (OR =1.50, 95% CI: 1.24-1.82, P<0.001), radiotherapy (OR =2.87, 95% CI: 1.71-4.82, P<0.001), lymph node (LN) dissection (OR =3.24, 95% CI: 1.44-7.31, P=0.005), and the number of LNs dissected (OR =2.34, 95% CI: 1.80-3.05, P<0.001). Egger's test showed that there was no publication bias among the literatures (P>0.05).ResultsA total of 12 retrospective studies with a total of 3,401 patients were included in this literature review. The incidence of lower extremity lymphedema after cervical cancer treatment was between 12.6% and 43.1%. Meta-analysis results demonstrated that the main risk factors were: body mass index (BMI) (OR =1.37, 95% CI: 1.10-1.71, P=0.005), age (OR =1.68, 95% CI: 1.07-2.64, P=0.02), International Federation of Gynecology and Obstetrics (FIGO) stage (OR =1.50, 95% CI: 1.24-1.82, P<0.001), radiotherapy (OR =2.87, 95% CI: 1.71-4.82, P<0.001), lymph node (LN) dissection (OR =3.24, 95% CI: 1.44-7.31, P=0.005), and the number of LNs dissected (OR =2.34, 95% CI: 1.80-3.05, P<0.001). Egger's test showed that there was no publication bias among the literatures (P>0.05).BMI, age, FIGO stage, radiotherapy, LN dissection and the number of LNs removed are the main risk factors for lower extremity lymphedema after cervical cancer treatment. When treating patients with cervical cancer, effective interventions should be sought to reduce the risk of lower extremity edema.ConclusionsBMI, age, FIGO stage, radiotherapy, LN dissection and the number of LNs removed are the main risk factors for lower extremity lymphedema after cervical cancer treatment. When treating patients with cervical cancer, effective interventions should be sought to reduce the risk of lower extremity edema.
Author Hu, Hongyuan
Huang, Xiujin
Fu, Mingru
Huang, Ju
Gao, Jinniao
Author_xml – sequence: 1
  givenname: Hongyuan
  surname: Hu
  fullname: Hu, Hongyuan
– sequence: 2
  givenname: Mingru
  surname: Fu
  fullname: Fu, Mingru
– sequence: 3
  givenname: Xiujin
  surname: Huang
  fullname: Huang, Xiujin
– sequence: 4
  givenname: Ju
  surname: Huang
  fullname: Huang, Ju
– sequence: 5
  givenname: Jinniao
  surname: Gao
  fullname: Gao, Jinniao
BookMark eNptkUtPHDEQhK0IBAS45Qf4yCGT-LHr8XCIFCHykJAiIZC4Wb09PcGJZ7yxvQvz7zGPHIJy6pL661Kp6y3bmeJEjL2T4oOSQrcfC6ZGqUaqpXnDDpSSXWOs0DtP2jamNTf77DjnX0IIJaVdCLPH9vXSarPU-oClS59_8wGwxJT5EBMP8Y4Sp_uSaPRl5mEe17fU0wgchlJXSGnrEQJHmKrmFYQy0lROOfA851LR4pEn2nq64zD1fKQCDUwQ5uzzEdsdIGQ6fpmH7PrL-dXZt-bix9fvZ58vGtRGlgatAFpIuwJDdtW1tu8X2A44mL7vgCwIsrIDi61BS7Yf2mVnAZQSFjRaqQ_Zp2ff9WY1Uo81YYLg1smPkGYXwbt_N5O_dT_j1nWq1fVx1eDkxSDFPxvKxY0-I4UAE8VNdsp0Uixa04mKqmcUU8w50eDQl_qF-Ojsg5PCPfXlal9OKffYVz16_-rob7b_4g9v05xX
CitedBy_id crossref_primary_10_3389_fphar_2022_1016138
crossref_primary_10_12701_jyms_2025_42_23
crossref_primary_10_17749_2949_5873_rehabil_2024_21
crossref_primary_10_17749_2313_7347_ob_gyn_rep_2023_461
crossref_primary_10_1016_j_asjsur_2024_12_037
crossref_primary_10_1186_s12905_024_03422_3
crossref_primary_10_3390_pharmaceutics15030868
crossref_primary_10_1038_s41598_023_43503_1
crossref_primary_10_1109_LRA_2024_3375709
crossref_primary_10_17749_2313_7347_ob_gyn_rep_2023_426
crossref_primary_10_1007_s00404_024_07886_4
crossref_primary_10_1097_NCC_0000000000001425
ContentType Journal Article
Copyright 2022 Translational Cancer Research. All rights reserved.
2022 Translational Cancer Research. All rights reserved. 2022 Translational Cancer Research.
Copyright_xml – notice: 2022 Translational Cancer Research. All rights reserved.
– notice: 2022 Translational Cancer Research. All rights reserved. 2022 Translational Cancer Research.
DBID AAYXX
CITATION
7X8
5PM
DOI 10.21037/tcr-22-1256
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
EISSN 2219-6803
EndPage 1721
ExternalDocumentID PMC9273676
10_21037_tcr_22_1256
GroupedDBID 53G
AAYXX
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CITATION
DIK
OK1
PGMZT
RPM
7X8
5PM
ID FETCH-LOGICAL-c361t-c80ae418ba6e8b978dd4c7fcf6dd9ae8a0e819a8c76c8e8df7598aa2208a3c813
ISSN 2218-676X
2219-6803
IngestDate Thu Aug 21 14:08:55 EDT 2025
Fri Jul 11 11:23:47 EDT 2025
Tue Jul 01 01:41:59 EDT 2025
Thu Apr 24 23:07:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 6
Language English
License Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c361t-c80ae418ba6e8b978dd4c7fcf6dd9ae8a0e819a8c76c8e8df7598aa2208a3c813
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributions: (I) Conception and design: H Hu, M Fu, J Gao; (II) Administrative support: X Huang; (III) Provision of study materials or patients: H Hu, M Fu, J Gao; (IV) Collection and assembly of data: H Hu, M Fu, J Gao; (V) Data analysis and interpretation: H Hu, M Fu, J Gao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
These authors contributed equally to this work.
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC9273676
PMID 35836533
PQID 2691047690
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9273676
proquest_miscellaneous_2691047690
crossref_citationtrail_10_21037_tcr_22_1256
crossref_primary_10_21037_tcr_22_1256
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-6-00
20220601
PublicationDateYYYYMMDD 2022-06-01
PublicationDate_xml – month: 06
  year: 2022
  text: 2022-6-00
PublicationDecade 2020
PublicationTitle Translational cancer research
PublicationYear 2022
Publisher AME Publishing Company
Publisher_xml – name: AME Publishing Company
SSID ssj0002118406
Score 2.2919562
SecondaryResourceType review_article
Snippet The main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main...
SourceID pubmedcentral
proquest
crossref
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1713
SubjectTerms Original
Title Risk factors for lower extremity lymphedema after cervical cancer treatment: a systematic review and meta-analysis
URI https://www.proquest.com/docview/2691047690
https://pubmed.ncbi.nlm.nih.gov/PMC9273676
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFMQGiXCYjwdNkSJzEdvY2IaZpEjygTepbZDvuVtSmU0getl-yn8vxJbdRpMFLVLmxe_m-not7_B2EPmhJVapKSXSUGZLGkO5I8PskUVSDf5GZcs0mvn1npxfp2SJbzGZ3o6qltlGf9O3OcyX_gyqMAa72lOw_INsvCgPwGPCFKyAM1wdh_MPWhXcdc2y94Nr2PDsEe1ubjesJcQNgmdJsZGgGrp1psJogFu16qDP3h57v6zr7cuGNaSSRQb1kHM06R7futhPDkkE-6GogjHNv2-ryph2oeNL6ov3qsm6HO8Pm9WLV_lxVfwyfteM9CsC7r6XypoxCIEEYdz0Lwet0YzlhIkomtjgecW5sWGPuj6wGJ20T110OgAYNAfBihNquLdkOne17_q-vSoR8yM0vYHZBaWFnP0KPKSQgdLQPZH08pM2QGbvOhd1H86cq3AKfRy8_jXeGJGZagjuKac6foachGcHHnln7aGaq56i2rMKBVRhYhR2rcM8qPLAKO1bhjlXYUwD3rDrCEg-cwp5TGDiFJ5x6gS5Ovp5_OSWhMwfRCYsbokUkTRoLJZkRKueiLFPNl3rJyjKXRsjIQKQpheZMCyPKJc9yISWlkZCJFnHyEu1V28q8Qjg1EeeamyjTeZrBHJEozSNN46WQhqVzdNh9f4UOsvW2e8q62AXXHH3s7772ci1_ue99B0UB9tT-SSYrs21_FZTlVr2E5dEc8QlG_YJWkX36TLW6csrsOSQDwIXXD3wXb9CT4dfyFu01dWveQYzbqANHt98zzbAU
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+factors+for+lower+extremity+lymphedema+after+cervical+cancer+treatment%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Translational+cancer+research&rft.au=Hu%2C+Hongyuan&rft.au=Fu%2C+Mingru&rft.au=Huang%2C+Xiujin&rft.au=Huang%2C+Ju&rft.date=2022-06-01&rft.issn=2218-676X&rft.eissn=2219-6803&rft.volume=11&rft.issue=6&rft.spage=1713&rft.epage=1721&rft_id=info:doi/10.21037%2Ftcr-22-1256&rft.externalDBID=n%2Fa&rft.externalDocID=10_21037_tcr_22_1256
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2218-676X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2218-676X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2218-676X&client=summon